Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia

by Vandana Singh, Benzinga Editor

July 8, 2021 9:28 AM | 27 seconds read | Make a Comment

Vor Biopharma Inc VOR has collaborated with Janssen Biotech Inc, a unit of Johnson & Johnson JNJ.
Under the terms of the collaboration, Vor Biopharma will investigate the combination of Vor's engineered hematopoietic stem cell (eHSC) platform with one of Janssen's bi-specific antibodies for acute myeloid leukemia (AML).
The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.
Price Action: VOR shares closed at $18.15 on Wednesday.